Panacea Biotec has initiated Phase III clinical trials for its dengue vaccine candidate, DengiALL, involving 10,335 participants at 19 sites across India, approved by the Drugs Controller General of India.
AI Assistant
Panacea Biotec Ltd
2024
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.